Mesco Pharmaceuticals Peer Comparison

NSE: MESCOPHARM | BSE: 500274

₹4.54

₹0.21 (4.85%)

As on 10-Jan-2022IST

Market cap

₹9 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

P/B Ratio

-0.9

Div. Yield

0 %

Edit

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	9	32,182	26,121	26,067	25,153
Revenue (₹ Cr)	--	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	-0.01	414.00	-371.81	387.35	288.22
Net Margin (%)	--	11.23	-3.93	26.01	14.79
RoE (%)	--	8.38	-3.85	25.18	29.77
Price to Earnings	--	78.69	--	67.49	87.27
Price-To-Book	-0.88	6.39	3.26	15.11	18.74

Income Statement (₹ Cr)

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	--	2,708.00	6,314.90	340.61	314.72
Total Income	0.00	2,840.00	6,479.01	341.99	324.85
Total Expenditure	0.00	2,771.00	4,886.94	260.45	223.05
EBITDA	0.00	-63.00	1,427.96	80.15	91.67
Depreciation	--	246.00	545.04	4.19	29.31
EBIT	0.00	-309.00	882.92	75.96	62.36
Interest	0.00	249.00	163.45	5.62	9.37
Other Income	--	132.00	164.11	1.38	10.13
Exceptional Items	--	-142.00	18.23	--	--
Profit before Tax	0.00	-568.00	949.05	71.73	63.12
Provision for Tax	--	-271.00	114.02	17.73	32.43
Profit after Tax	0.00	-297.00	835.03	54.00	30.69

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	-11.02	3,376.00	5,605.00	166.93	374.15
Minority Interest	--	383.00	--	--	0.00
Non-Current Liabilities	11.18	496.00	2,560.38	80.29	52.94
Current Liabilities	0.02	3,121.00	2,590.70	166.04	111.16
Total Liabilities	0.18	7,746.00	10,777.71	413.27	538.25

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	0.18	4,951.00	7,006.96	190.83	201.99
Current Assets	0.00	2,281.00	3,749.12	216.23	336.26
Total Assets	0.18	7,746.00	10,777.71	413.27	538.25
Total Debt*	11.18	2,332.00	2,910.19	136.64	93.28
Net Current Assets	-0.01	-840.00	1,158.42	50.19	225.10
Contingent Liabilities	--	639.00	29.98	0.00	30.36

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	0.00	-287.00	597.58	27.96	56.87
Cash Flow from Investing Activities	--	1,470.00	-4,479.93	-101.21	-36.45
Cash from Financing Activities	-0.03	-1,171.00	3,976.83	72.11	52.49
Net Cash Inflow / Outflow	-0.04	12.00	94.48	-1.14	72.91

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	-2.08	-5.50	13.06	33.43	17.30
ROE (%)	0.00	-9.92	14.90	40.51	8.84
ROA (%)	-1.99	-3.93	7.76	16.74	6.36
EBIT Margin (%)	--	2.55	25.21	23.94	32.35
Net Margin (%)	--	-10.46	12.89	15.79	9.45
Cash Profit Margin (%)	--	-1.10	19.71	17.08	19.06

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	--	-4.78	0.00	42.13	19.65
EBIT Growth (%)	96.07	-56.28	--	85.90	3.17
Net Profit Growth (%)	95.93	-115.30	0.00	96.57	-37.89
EPS Growth (%)	95.98	1,097.71	0.00	-34.47	-37.89
Book Value Growth (%)	-0.04	26.74	0.00	51.79	8.89

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	0.00	6.12	0.00	0.00	0.00
Price / Book Value	0.00	1.36	0.00	0.00	0.00
Dividend Yield (%)	--	0.00	--	--	--
EV/EBITDA	-7,999.21	95.62	2.20	2.03	0.14
Market Cap (₹ Cr)	--	4,557.85	0.00	0.00	0.00

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	-1.02	0.70	0.52	0.85	0.26
Short term debt to equity ratio	--	0.32	0.06	0.27	0.12
Current Ratio	0.18	0.73	1.45	1.30	3.02
Quick Ratio	0.18	0.47	0.97	0.94	2.46
Interest Coverage	-28.38	-1.28	6.81	13.77	7.74

	Mesco Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	--	33.90	24.94	35.43	43.28
Asset Turnover	0.00	0.61	0.65	1.06	0.65
Receivable days	--	85.04	82.08	94.89	160.21
Inventory Days	--	59.63	64.21	60.39	58.00
Payable days	--	255.87	162.72	138.36	183.24
Cash Conversion Cycle	--	-111.19	-16.42	16.92	34.97

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.